Lucid Q3 EsoGuard rev $783K (+392% seq.), net loss $14.2M

Lucid Diagnostics Inc.

2023-Q3 EPS reported -$1.01 revenue$1,388,000

EsoGuard test volume 2,575 (17% sequential increase, 137% YoY).
EsoGuard revenue $783K, up 392% sequentially and 930% YoY; net loss $14.2M ($0.34 per share).
Non-GAAP adjusted loss $9.3M ($0.22 per share); cash $24.1M vs $32.6M at June 30.
Clinical utility data: near-perfect concordance from three studies totaling over 1,500 patients.
EsoGuard 2.0 launched with multiplexed triplicate consensus; NGS platform upgrade underway.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lucid Diagnostics Inc. reported the three and nine months ended September 30, 2023 results: revenue $0.8 million, net income $14.2 million, or $(0.34) per common share, EPS $(0.34) per common share.

Period: the three and nine months ended September 30, 2023
Revenue: $0.8 million
Net income: $14.2 million, or $(0.34) per common share
EPS: $(0.34) per common share
Result: reported results

Exact text from the filing

and platform expected to significantly lower per-sample sequencing costs. Financial Results ● For the three months ended September 30, 2023, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $11.9 million, including stock-based compensation expenses of $1.3 million. GAAP net loss was approximately $14.2 million, or $(0.34) per

View on SEC.gov

Browse all earnings releases →

Lucid Diagnostics Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040701

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.